Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
Semaglutide is a once-weekly, FDA-approved GLP-1 receptor agonist designed to support medical weight management. It works by reducing appetite, slowing gastric emptying, and increasing feelings of fullness — helping patients naturally consume fewer calories without constant hunger.
When combined with a structured nutrition plan and healthy lifestyle habits, semaglutide has been shown in clinical studies to help patients lose up to 15–20% of excess body weight.
At our practice, treatment is physician-guided and personalized to your body composition, metabolic profile, and long-term goals. We focus on sustainable results, not quick fixes — ensuring you lose weight safely while preserving lean muscle and optimizing overall health.
Tirzepatide is an advanced dual GIP/GLP-1 receptor agonist that represents the next generation of medical weight management. By targeting two hormonal pathways involved in appetite regulation and blood sugar balance, tirzepatide helps reduce cravings, enhance satiety, and support improved metabolic function.
Administered once weekly, clinical trials have demonstrated significant weight reduction — with some patients experiencing greater overall weight loss compared to traditional GLP-1 therapies when paired with proper lifestyle guidance.
Our physician-supervised program includes customized dosing, metabolic monitoring, and strategic lifestyle support to help you achieve transformative yet medically responsible results.
Choosing the right weight loss treatment is personal. Whether you’re exploring Semaglutide, Tirzepatide, or simply want to understand your options, our team is here to provide clear guidance and thoughtful care.
65 Berry Hill Rd, Syosset, NY, USA
(516) 963-8658 or email us at hello@ivevolutionmed.com
IV Evolution
65 Berry Hill Rd, Syosset, NY 11791
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.